T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Argan
AGX
$8.02B
| $17.8M | ﹤0.01% |
56,655
+9,926
| +21% | +$3.15M |
|
1077
Interparfums
IPAR
$3.78B
| $17.7M | ﹤0.01% |
209,065
+1,448
| +0.7% | +$127K |
|
1078
Clean Harbors
CLH
$16.9B
| $17.6M | ﹤0.01% |
75,101
-2,153
| -3% | -$492K |
|
1079
Illumina
ILMN
$29.1B
| $17.6M | ﹤0.01% |
133,917
+4,360
| +3% | +$512K |
|
1080
PAR Technology
PAR
$770M
| $17.5M | ﹤0.01% |
481,733
+151,961
| +46% | +$5.48M |
|
|
CPRX
1081
DELISTED
Catalyst Pharmaceutical
CPRX
| $17.5M | ﹤0.01% |
748,781
+5,106
| +0.7% | +$114K |
|
1082
Hudbay
HBM
$11.8B
| $17.5M | ﹤0.01% |
+879,900
| New | +$14.9M |
|
1083
First Citizens BancShares
FCNCA
$25.6B
| $17.4M | ﹤0.01% |
8,114
-3
| -0% | -$5.66K |
|
1084
Agios Pharmaceuticals
AGIO
$2.04B
| $17.4M | ﹤0.01% |
637,886
-1,019,052
| -62% | -$35.8M |
|
1085
LegalZoom.com
LZ
$930M
| $17.3M | ﹤0.01% |
1,745,359
-704,898
| -29% | -$6.99M |
|
1086
Builders FirstSource
BLDR
$7.79B
| $17.2M | ﹤0.01% |
166,984
-2,220
| -1% | -$249K |
|
1087
Solventum
SOLV
$14.5B
| $17.2M | ﹤0.01% |
216,568
+657
| +0.3% | +$50.3K |
|
|
EXAS
1088
DELISTED
Exact Sciences
EXAS
| $17.1M | ﹤0.01% |
168,554
-1,554,145
| -90% | -$125M |
|
1089
Core & Main
CNM
$8.64B
| $17.1M | ﹤0.01% |
328,593
+13,679
| +4% | +$702K |
|
1090
Globe Life
GL
$13.8B
| $17M | ﹤0.01% |
121,772
-1,633
| -1% | -$221K |
|
1091
TTM Technologies
TTMI
$14.6B
| $16.9M | ﹤0.01% |
245,107
+12,648
| +5% | +$826K |
|
1092
HF Sinclair
DINO
$15.6B
| $16.8M | ﹤0.01% |
365,048
-2,016,287
| -85% | -$104M |
|
1093
HEICO Corp Class A
HEI.A
$38B
| $16.8M | ﹤0.01% |
66,547
+4,371
| +7% | +$1.08M |
|
1094
Host Hotels & Resorts
HST
$15.6B
| $16.7M | ﹤0.01% |
940,116
+1,971
| +0.2% | +$34K |
|
1095
Amer Sports
AS
$19.3B
| $16.6M | ﹤0.01% |
444,892
+104,235
| +31% | +$3.58M |
|
1096
iShares MSCI ACWI ex US ETF
ACWX
$12B
| $16.6M | ﹤0.01% |
247,240
| – | – |
|
1097
Kyverna Therapeutics
KYTX
$500M
| $16.6M | ﹤0.01% |
1,762,617
+250,418
| +17% | +$1.86M |
|
|
SNV
1098
DELISTED
Synovus
SNV
| $16.5M | ﹤0.01% |
329,722
+164,953
| +100% | +$7.93M |
|
1099
Fluor
FLR
$6.96B
| $16.4M | ﹤0.01% |
414,750
+2,941
| +0.7% | +$130K |
|
1100
LyondellBasell Industries
LYB
$20.2B
| $16.4M | ﹤0.01% |
379,505
+5,931
| +2% | +$269K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.